Rick Doblin is executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS), which he founded in 1986 and grew into an international psychedelic pharmaceutical company with over 50 staff. MAPS, which designs or sponsors psychedelic psychotherapy drug development research, received FDA Breakthrough Therapy Designation for MDMA-assisted psychotherapy for PTSD in 2017, with Phase 3 clinical trials underway and FDA approval anticipated in 2021. Doblin, whose PhD dissertation was on the regulation of psychedelic research and prescription use, has a professional goal to become a legally licensed psychedelic psychotherapist by developing legal contexts for safe uses of psychedelics and marijuana as prescription medicines and for personal growth, spirituality, and creativity.
Highlights
Previously
Ketamine has sometimes been called the “date rape drug” because its sedative properties have enabled sexual assaults — but a groundbreaking study suggests it can also reduce s...
Resources
Mental Health is Getting the Psychedelic Treatment